What is PAVM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PAVM?

P/E (TTM) is n/a and 52-week range is $2.60 to $28.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PAVM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PAVM?

The company profile lists revenue (TTM) near $128K, net income (TTM) near $-1.38B, EPS (TTM) near $-9.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PAVmed Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 7.2M shares outstanding, ISIN US70387R5028 when available from company profile and filing metadata.

PAVmed Inc

$PAVM

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$2.79

+3.72%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. The company is headquartered in New York City, New York and currently employs 41 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Employees

Website

pavmed.com/

IPO

2016-07-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)